Business
Resverlogix Hosts Symposium to Discuss the Role of BET-inhibition in Modifying Cardiovascular Risk at the ESC Congress in Rome, Italy
Resverlogix Hosts Symposium to Discuss the Role of BET-inhibition in Modifying Cardiovascu...
About this update from Resverlogix Corp.
[{"type":"text","content":"\n\n\n\nResverlogix Hosts Symposium to Discuss the Role of BET-inhibition in Modifying Cardiovascular Risk at the ESC Congress in Rome, Italy\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nResverlogix Hosts Symposium to Discuss the Role of BET-inhibition in Modifying Cardiovascular Risk at the ESC Congress in Rome, Italy\nCanada NewsWire\nCALGARY, Aug. 29, 2016\n\n\n\nThe presentations at the ESC Congress symposium highlighted apabetalone and the opportunity and need for a novel approach to the treatment of high risk cardiovascular disease and diabetes.\n\n\n\nCALGARY, Aug. 29, 2016 /CNW/ - Resverlogix Corp. (\"Resverlogix\" or the \"Company\") (TSX:RVX) today announced that on Sunday, August 28, 2016, at the European Society of Cardiology (ESC) Congress in Rome, Italy, the Company hosted a symposium entitled \"A novel approach for high CV risk patients with diabetes: The potential of epigenetics.\"\n\nThe speakers and agenda were as follows:\n\nIntroductionStefano Del Prato, MD - Università di Pisa, Pisa, Italy\n\nThe High Risk Diabetes patient with cardiovascular disease:What else can we target to reduce cardiovascular risk?Kausik Ray, MD - Imperial College London, United Kingdom\n\nUnderstanding BET inhibition as a novel pathway for cardiovascular risk modulationJorge Plutzky, MD - Brigham and Women's Hospital, Harvard Medical School, Boston, USA\n\nBET inhibition in cardiovascular disease: A new dawn?John Kastelein, MD - Academic Medical Centre, Amsterdam, The Netherlands\n\nDiscussion & summaryStefano Del Prato, MD - Kausik Ray, MD\n\nPresentations will be made available at: www.pace-cme.org.\n\nDonald J. McCaffery, President and CEO commented, \"The presentations at the ESC Congress symposium highlighted apabetalone and the opportunity and need for a novel approach to the treatment of high risk cardiovascular disease and diabetes. Moreover, data presented demonstrated the important role for epigenetics in the underlying pathology of these diseases\". McCaffrey added that \"based on its mechanism, we believe that apabetalone has the potential to ...